AzurRx BioPharma to acquire First Wave Bio for $229m

0
388

AzurRx BioPharma has signed a definitive agreement to acquire First Wave Bio in a stock and cash deal valued at $229m, comprising specific development, regulatory and sales milestones.

A clinical-stage biotechnology company, First Wave Bio focuses on developing new, gut-targeted, small molecule treatments for auto-immune inflammatory bowel diseases (IBD) and various serious ailments.

Read more: https://www.pharmaceutical-technology.com/news/azurrx-biopharma-first-wave-bio-229m/